Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 842 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Gilead Sciences Clear all
Terminated Phase 1Phase 2 Interventional Results available

An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

NCT01090414
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin
Interventions
Idelalisib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
18
States / cities
Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 7, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

NCT03631732
View directory record Official record
Conditions
HIV-1 Infection
Interventions
B/F/TAF, NRTIs, Third Agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
82
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 7, 2026, 2:29 AM EDT
Recruiting Phase 2 Interventional

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

NCT05838521
View directory record Official record
Conditions
Cervical Cancer
Interventions
Sacituzumab govitecan
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 7, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

NCT01815736
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
91
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 7, 2026, 2:29 AM EDT
Completed Phase 3 Interventional

ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

NCT00208299
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson, Adenosine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2009 · Synced Oct 7, 2026, 2:29 AM EDT
Terminated Phase 2 Interventional Results available

Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)

NCT01759511
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Simtuzumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 7, 2026, 2:29 AM EDT
Terminated Phase 2 Interventional Results available

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

NCT02258529
View directory record Official record
Conditions
Follicular Lymphoma, Small Lymphocytic Lymphoma
Interventions
Idelalisib, Rituximab
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Long Beach, California • Fort Myers, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 7, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate

NCT02885181
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GS-9876, Filgotinib, GS-9876 placebo, Filgotinib placebo, Methotrexate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
DeBary, Florida • Sarasota, Florida • Canton, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 7, 2026, 2:29 AM EDT
Terminated No phase listed Observational Results available

A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

NCT02292706
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Sofosbuvir, Ribavirin, LDV/SOF, SOF/VEL, SOF/VEL/VOX, Other SOF-Based Regimen, Ineligible parent treatment
Drug · Other
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
77
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 57 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 7, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

NCT04772989
View directory record Official record
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
Interventions
AB308, Zimberelimab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
Los Angeles, California • Jacksonville, Florida • Goshen, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 7, 2026, 2:29 AM EDT
Available No phase listed Expanded access

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

NCT05776160
View directory record Official record
Conditions
Large B-cell Lymphoma, Follicular Lymphoma
Interventions
Axicabtagene Ciloleucel
Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
U.S. locations
52
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 7, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

Phase Ib Study of SC Milatuzumab in SLE

NCT01845740
View directory record Official record
Conditions
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System, Lupus Nephritis
Interventions
milatuzumab, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 7, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy

NCT02886728
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, MTX, Placebo to match MTX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
45
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 7, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Results available

An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)

NCT01338636
View directory record Official record
Conditions
Exercise-induced Pulmonary Arterial Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 7, 2026, 2:29 AM EDT
Active, not recruiting Phase 3 Interventional

Entecavir to TAF Switch

NCT03489239
View directory record Official record
Conditions
Hepatitis B
Interventions
Tenofovir Alafenamide
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 7, 2026, 2:29 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Botswana TDF/FTC Oral HIV Prophylaxis Trial

NCT00448669
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg, Placebo Oral Tablet
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 39 Years
Enrollment
1,219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 7, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)

NCT01769456
View directory record Official record
Conditions
HIV Infection
Interventions
PCC, Emtricitabine/tenofovir (FTC/TDF (Truvada®))
Behavioral · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 17 Years · Male only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 7, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies

NCT00504972
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Interventions
hLL1
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 7, 2026, 2:29 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

NCT00874796
View directory record Official record
Conditions
HCV Infection
Interventions
GS-9450, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 7, 2026, 2:29 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy

NCT07743541
View directory record Official record
Conditions
Uterine Endometrial Cancer
Interventions
TUB-040 - Dose escalation, TUB-040 - RP2D
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Los Angeles, California • East Brunswick, New Jersey • Lake Success, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 7, 2026, 2:29 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286
View directory record Official record
Conditions
Triple Negative Breast Cancer, PD-L1 Positive
Interventions
Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
247
States / cities
Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 175 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 7, 2026, 2:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

NCT04989803
View directory record Official record
Conditions
Relapsed and/or Refractory B-cell Lymphoma
Interventions
Cyclophosphamide, Fludarabine, KITE-363, KITE-753
Drug · Biological
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
21
States / cities
Gilbert, Arizona • Duarte, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 7, 2026, 2:29 AM EDT
Recruiting Phase 4 Interventional

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

NCT07476339
View directory record Official record
Conditions
HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
Interventions
Bictegravir, emtricitabine, and tenofovir alafenamide
Drug
Lead sponsor
CAN Community Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Clearwater, Florida • Ft. Pierce, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 7, 2026, 2:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers

NCT03038763
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
Eligibility Screening, HCV test
Other · Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 72 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 7, 2026, 2:29 AM EDT